|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400084474 |
|
最近更新日期: Date of Last Refreshed on: |
2024-05-17 10:14:34 |
|
注册时间: Date of Registration: |
2024-05-17 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
NLMR对脓毒性休克患者死亡风险的预测作用 |
|
Public title: |
Predictive value of NLMR for the risk of death in patients with septic shock |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脓毒性休克患者住院死亡风险的预测 |
|
Scientific title: |
Prediction of in-hospital mortality risk in patients with septic shock |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林小明 |
研究负责人: |
林小明 |
|
Applicant: |
Lin Xiaoming |
Study leader: |
Lin Xiaoming |
|
申请注册联系人电话: Applicant telephone: |
+86 188 5920 9870 |
研究负责人电话: Study leader's telephone: |
+86 188 5920 9870 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lin.xiaoming@zsxmhospital.com |
研究负责人电子邮件: Study leader's E-mail: |
lin.xiaoming@zsxmhospital.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省厦门市湖里区金湖路668号 |
研究负责人通讯地址: |
福建省厦门市湖里区金湖路668号 |
|
Applicant address: |
668 Jinhu Road, Huli District, Xiamen City, Fujian Province |
Study leader's address: |
668 Jinhu Road, Huli District, Xiamen City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
361000 |
研究负责人邮政编码: Study leader's postcode: |
361000 |
|
申请人所在单位: |
复旦大学附属中山医院厦门医院 |
||
|
Applicant's institution: |
Xiamen Branch, Zhongshan Hospital, Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属中山医院厦门医院 |
||
|
Affiliation of the Leader: |
Xiamen Branch, Zhongshan Hospital, Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
B2023-024 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属中山医院厦门医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Xiamen Branch, Zhongshan Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-04-18 00:00:00 |
||
|
伦理委员会联系人: |
米宏霏 |
||
|
Contact Name of the ethic committee: |
mi hongfei |
||
|
伦理委员会联系地址: |
福建省厦门市湖里区金湖路668号 |
||
|
Contact Address of the ethic committee: |
668 Jinhu Road, Huli District, Xiamen City, Fujian Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 592 356 9860 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属中山医院厦门医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiamen Branch, Zhongshan Hospital, Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市湖里区金湖路668号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
668 Jinhu Road, Huli District, Xiamen City, Fujian Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2021年厦门市医疗卫生指导性项目(课题号:3502Z20214ZD1082) |
||||||||||||||||||||||
|
Source(s) of funding: |
Xiamen Medical and Health Guiding Project in 2021 (Project number: 3502Z20214ZD1082) |
||||||||||||||||||||||
|
Target disease: |
Septic shock |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
探讨NLMR对脓毒性休克患者预后的预测价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the prognostic value of NLMR in patients with septic shock. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
① 接受血管活性药物治疗脓毒性休克患者。 ② 纳入患者符合国际疾病分类编码(ICD-9)脓毒性休克(编码为 78552)诊断,且在入 ICU±24 h 期间已留血培养并已用抗生素治疗且最差 SOFA≥2 分。 |
||||||||||||||||||||||
|
Inclusion criteria |
① Patients with septic shock were treated with vasoactive drugs. ② Included patients were diagnosed with International Classification of Diseases Code (ICD-9) septic shock (code 78552), had blood culture and antibiotics within ±24 h of ICU admission, and the worst SOFA score was ≥2. |
||||||||||||||||||||||
|
排除标准: |
排除标准:年龄<16 岁;多次入 ICU 的患者;缺少计算各评分系统的重要生理学参数。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: age < 16 years old; Patients admitted to ICU multiple times; Important physiological parameters for calculating each scoring system are missing. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-04-20 00:00:00至 To 2023-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-04-20 00:00:00 至 To 2023-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
figshare,网址:https://doi.org/10.6084/m9.figshare.25183694.v1 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
figshare,URL:https://doi.org/10.6084/m9.figshare.25183694.v1 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据收集:根据患者住院期间28 d生存状态分为存活组和死亡组。收集两组患者的以下临床信息:(1)一般资料,包括性别、年龄、体质量指数、感染来源、合并症,采用Elixhauser合并症指数(ECI)评估合并症情况;(2)入重症加强治疗病房(ICU) 24 h内最异常的实验室检查结果包括血细胞分析指标[中性粒细胞计数(N)、单核细胞计数(M)、淋巴细胞计数(L)]、血红蛋白(Hb)、血小板计数(PLT)和血生化指标[血乳酸(Lac)、总胆红素(TBIL)、血小板计数(PLT)]。血尿素氮(BUN)、肌酐(Cr)、氧合指数(P/F)、c反应蛋白(CRP)、降钙素原(PCT)。根据入院失败评估后24 h内各指标最差值计算格拉斯哥昏迷量表(GCS)评分、快速序贯器官衰竭评估(qSOFA)评分、序贯器官衰竭评估(SOFA)评分、急性生理学与慢性健康状况评估ⅱ(APACHEⅱ)评分;(3)入ICU 24h内的干预措施:机械通气、24h内最大去甲肾上腺素当量(NEE24hmax)、肾脏替代治疗等。 数据管理:采用EXCEL表格进行电子数据收集,数据录入和管理,试验中收集的数据录入到数据库中,并通过预先设计好的核查规则对录入的数据进行核实、确认,有问题的数据发出质疑并获得解答以及对数据进行相应的更新等。对已收集的数据进行标准化编码,以便后续的数据分析。数据清理与审核,数据录入、核查完成后,对全部数据做最后的核查、清理、更新等,对患者个人信息进行隐蔽,不涉及人类遗传学信息。数据确认质量符合预期标准后,将数据锁定,导入IBM SPSS进行数据分析整理,并将数据和相关工作文档归档,保存,上传至figshare共享平台。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: Patients were categorized into survival and death groups based on their 28-day survival status during hospitalization. The following clinical information of the patients in both groups was collected: (1) general data, including sex, age, body mass index, source of infection, and comorbidities assessed using the Elixhauser comorbidity index (ECI);(2) the most abnormal laboratory results within 24 h of intensive care unit (ICU) admission included blood cell analysis indexes, such as neutrophil count (N), monocyte count (M), lymphocyte count (L), hemoglobin (Hb), platelet count (PLT), and blood biochemical indexes, such as blood lactic acid (Lac), total bilirubin (TBIL), blood urea nitrogen (BUN), creatinine (Cr), oxygenation index (P/F), C-reactive protein (CRP), and procalcitonin (PCT) . The Glasgow Coma Scale (GCS) score, quick Sequential Organ Failure Assessment (qSOFA) score, Sequential Organ Failure Assessment (SOFA) score, and Acute Physiology and Chronic Health Evaluation II (APACHE II) score were calculated according to the worst value of each index within 24 h after admission failure assessment; and (3) interventions conducted within 24 h after admission to ICU were as follows: mechanical ventilation, maximum norepinephrine equivalent within 24 h (NEE24hmax),and renal replacement therapy, among others. Data management: EXCEL was used for electronic data collection, data entry and management, the data collected in the trial were entered into the database, and the data were verified and confirmed through the pre-designed verification rules, the data were questioned and answered, and the data were updated accordingly. The collected data were standardized and coded for subsequent data analysis. After data entry and verification, all data were checked, cleaned, updated, etc. Personal information of patients was concealed, and no human genetic information was involved. After confirming that the quality of the data met the expected standards, the data were locked, imported into IBM SPSS for data analysis and sorting, and the data and related work documents were archived, saved, and uploaded to the figshare sharing platform. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |